Estíbaliz Miranda

876 citations
17 papers · 232 indexed · h-index 8

Estíbaliz Miranda

16 papers receiving 227 citations

Peers

Estíbaliz Miranda
Comparison fields: 5 of 55
  • Hematology 50
  • Molecular Biology 191
  • Public Health, Environmental and Occupational Health 43
  • Cancer Research 21
  • Genetics 13
Replace Blerim Marovca with:
Blerim Marovca Switzerland
Laura Hinze Germany
Guillermo Garcia-Manero United States
Jorge Vaz Pinto Neto Brazil
Bruno A. Lopes Brazil
Bonnie Le United States
Hayato Tamai Japan
Valeria Cazzaniga Italy
Emanuela Ferrari Italy
Clarissa Kooi Netherlands
Estíbaliz Miranda relative to Blerim Marovca Switzerland Blerim Marovca's profile →
Citations per field
00.5×1.7×
Blerim Marovca · 1×
Citations per year

Countries citing papers authored by Estíbaliz Miranda

Since Specialization
Citations

This map shows the geographic impact of Estíbaliz Miranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Estíbaliz Miranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Estíbaliz Miranda more than expected).

Fields of papers citing papers by Estíbaliz Miranda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Estíbaliz Miranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Estíbaliz Miranda. The network helps show where Estíbaliz Miranda may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Estíbaliz Miranda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Estíbaliz Miranda Line = papers co-authored together Estíbaliz Miranda links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1 20240
2 20227
3 202122
4 201918
5 20191
6 201823
7 201711
8 201716
9 201738
10 20142
11 201238
12 20113
13 201142
14 20012
15 20002
16
[Fanconi's anemia].
19996
17
[WAGR syndrome: a case report].
19981

About Estíbaliz Miranda

Estíbaliz Miranda is a scholar working on Hematology, Molecular Biology and Genetics, having authored 17 papers that have together received 232 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (5 papers), Histone Deacetylase Inhibitors Research (5 papers), Acute Myeloid Leukemia Research (4 papers), Protein Degradation and Inhibitors (4 papers), Acute Lymphoblastic Leukemia research (3 papers), CRISPR and Genetic Engineering (2 papers), Pluripotent Stem Cells Research (1 paper) and Single-cell and spatial transcriptomics (1 paper). The work is most often cited by research in Hematology (50 citations), Molecular Biology (191 citations) and Public Health, Environmental and Occupational Health (43 citations). Estíbaliz Miranda has collaborated with scholars based in Spain, China and Germany. Frequent co-authors include Xabier Agirre, Felipe Prósper, Leire Gárate, Edurne San José‐Eneriz, Amaia Vilas‐Zornoza, José I. Martı́n-Subero, J. Rifón, Iñigo Apaolaza, Marı́a José Calasanz and Francisco J. Planes. Their work appears in journals such as Nature Communications, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026